Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MacroGenics, Gilead pair up on DART project
February 2013
SHARING OPTIONS:

ROCKVILLE, Md.A license agreement was established between MacroGenics and Gilead Sciences in early January to develop and commercialize Dual-Affinity Re-Targeting products aimed at up to four undisclosed targets. Per the agreement, Gilead will pay up to $30 million total in license fee payments, as well as potentially $85 million in preclinical milestones across the four programs. MacroGenics is also eligible for approximately $1 billion in milestone payments if all four programs reach the required clinical, regulatory and commercialization milestones, and stands to receive tiered royalties on future net sales. In return, Gilead holds exclusive worldwide rights for three of the programs, and will fully fund MacroGenics' research activities for the four programs. Dr. Scott Koenig, MacroGenics' president and CEO, said the collaboration "represents the latest validation of our ongoing efforts."    

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.